If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 41 - 50 of 270

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Objective
This study is being done to answer the following question: Can we improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by adding an investigational drug called inotuzumab ozogamicin (hereafter, inotuzumab) to lower doses of the usual chemotherapy for acute lymphoblastic leukemia?
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
Protocol No
ALLIANCE-A042001

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Objective
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Protocol No
RTOG-1216